People In Health Care
Professor Rosemary Harrup, Tasmania
Rosemary Harrup trained in Victoria and Tasmania in Medical Oncology and Clinical Haematology, completing a dual Fellowship in 2001. She is the current Director of Cancer and Blood Services at the Royal Hobart Hospital (RHH), a role she has held since 2009.
External to the RHH she is a member of the board of the Cancer Council of Tasmania, the Tasmanian Cancer Registry Advisory Group and the RHH Research Foundation Scientific and Advisory Committee.
Rosemary is currently Deputy Chair of the Cooperative Trials Group for Neuro oncology (COGNO), a member of the Australian Brain Cancer Mission Steering Committee and the Australian Cancer Plan Tasmanian jurisdictional representative. She has a strong interest in clinical research, particularly in the areas of Clinical Trials in Brain Cancer, Malignant Haematology and Late Effects and is an active mentor for early career researchers.
Australian Health Journal spoke to Rosemary about her journey in medicine and specifically her work in Clinical Trials in Brain Cancer and the value she placed on her senior clinicians as mentors and how she now mentors others.
-
HEALTH CARE BRIEF: Type 1 Diabetes (T1D)
Type 1 Diabetes – Incidence rates, management, lived experience & research
-
Evolution in consumer diagnostics with saliva based pathology
Since the COVID-19 pandemic, consumer diagnostics have rapidly advanced, with more people becoming aware of and comfortable using at-home testing. These tests provide greater convenience, control, and empowerment, allowing individuals to monitor their health without immediately consulting a healthcare professional. Recently, this shift has been particularly impactful in areas such as pregnancy testing, where saliva-based diagnostics now enable earlier and more accessible detection.
-
Most Valuable Women in Leadership 2020
ANDHealth Co-Founder and Managing Director Bronwyn Le Grice pioneered the unique non-profit industry-led model supporting Australian digital health companies navigate the commercialisation path to institutional investment and international market entry.
